Technical Analysis for CSBTF - Kuros Biosciences Ltd

Grade Last Price % Change Price Change
grade D 1.75 -35.90% -0.9800
CSBTF closed down 35.9 percent on Friday, August 9, 2019, on approximately normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical CSBTF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week Low Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%

Older signals for CSBTF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company's synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion; and KUR-112 that consists of a natural healing matrix combined with a targeted bone growth factor intended to be applied as a single percutaneous injection into solitary bone cysts. The company has collaborations with Checkmate Pharmaceuticals LLC for the licensing of CYT003 for the treatment of oncology; Pfizer Inc. to develop a novel anti-IgE vaccine; and Singapore's Agency for Science, Technology and Research, which researches, develops, and commercializes an influenza vaccine. Kuros Biosciences AG was founded in 2000 and is headquartered in Schlieren, Switzerland.
RTT Biopharmaceutical European Union Influenza Biopharmaceutical Products Chronic Diseases Bone Fractures
Is CSBTF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 3.96
52 Week Low 1.75
Average Volume 7,643
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 2.791
10-Day Moving Average 2.642
Average True Range 0.3133
ADX 0.0
+DI 30.013
-DI 57.1999
Chandelier Exit (Long, 3 ATRs ) 2.3301
Chandelier Exit (Short, 3 ATRs ) 2.6899
Upper Bollinger Band 3.4151
Lower Bollinger Band 2.1669
Percent B (%b) -0.33
BandWidth 44.722322
MACD Line -0.1846
MACD Signal Line -0.0748
MACD Histogram -0.1098
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.2350
Resistance 3 (R3) 3.4000 3.0700 2.9875
Resistance 2 (R2) 3.0700 2.6918 2.9875 2.9049
Resistance 1 (R1) 2.4100 2.4582 2.2450 2.2450 2.8225
Pivot Point 2.0800 2.0800 1.9975 1.9975 2.0800
Support 1 (S1) 1.4200 1.7018 1.2550 1.2550 0.6775
Support 2 (S2) 1.0900 1.4682 1.0075 0.5951
Support 3 (S3) 0.4300 1.0900 0.5125
Support 4 (S4) 0.2650